Amyloidosis Treatment Market To Reach $8.91 Billion By 2030

Amyloidosis Treatment Market Growth & Trends

The global amyloidosis treatment market size is expected to reach USD 8.91 billion by 2030, registering to grow at a CAGR of 7.4% from 2024 to 2030 according to a new report by Grand View Research, Inc. Several factors such as increased adoption of novel targeted therapies and transplantations, emergence of biologics, and rising geriatric population are driving the market.

Amyloidosis is a group of rare diseases where misfolded aggregates of proteins (amyloids) buildup in tissues and organs. AL amyloidosis is the most common type of amyloidosis in U.S., with approximately 3,000 to 4,000 new cases diagnosed annually. Although in majority of cases, the disease is diagnosed in people over the age of 60, there are a few cases of people being diagnosed in their late 20s and about two-thirds of the patients are male.

Stem cell transplants and targeted therapies are gaining traction in developed countries. However, amyloidosis cohorts in endemic regions do not have access to sufficient healthcare infrastructure to ensure prompt diagnosis and treatment in underdeveloped countries. Chemotherapy and supportive care are anticipated to lose market share over the forecast period due to adverse side effects and lower efficacy.

 Request a free sample copy or view report summary: Amyloidosis Treatment Market Report

Amyloidosis Treatment Market Report Highlights

• The chemotherapy segment dominated the market in 2023 with a share of 26.5% owing to its effectiveness in managing amyloidosis, particularly AL amyloidosis. Chemotherapy targets and destroys the abnormal plasma cells that produce amyloid proteins, thereby reducing the production of these harmful proteins and alleviating symptoms.

• Hospitals and clinics have secured the dominant market share of 49.3% in 2023 owing to the rising incidence of amyloidosis, among the aging population that prefer specialized healthcare services. Amyloidosis often requires a comprehensive treatment approach involving various medical specialties, including cardiology, nephrology, and hematology.

• The North America amyloidosis treatment market marked a lucrative share of 39.4% in 2023 pertaining to the presence of a well-established healthcare infrastructure and growing awareness regarding amyloidosis diseases.

Amyloidosis Treatment Market Segmentation

Grand View Research has segmented the global amyloidosis treatment market based on treatment, end-use, and region:

Amyloidosis Treatment Treatment Outlook (Revenue, USD Million, 2018 - 2030)

• Chemotherapy

• Immunosuppressive Drugs

• Transplantation

• Supportive Care

• Surgery

• Others

Amyloidosis Treatment End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals & Clinics

• Ambulatory Surgical Centers

• Home Care Settings

• Others

Amyloidosis Treatment Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in Amyloidosis Treatment Market

• Pfizer Inc.

• Johnson & Johnson Services, Inc.

• GSK plc

• Takeda Pharmaceutical Company Limited

• Amgen Inc.

• Bristol-Myers Squibb Company

• Novartis AG

• F. Hoffmann-La Roche Ltd

• Merck KGaA

• Sanofi

• Alnylam Pharmaceuticals, Inc.